Schlaganfallrisiko und Mortalität

Die Frage nach Effektivität und Sicherheit einer oralen Antikoagulation (OAK) bei Dialysepatienten mit Vorhofflimmern (VHF) zur Reduktion eines erhöhten Risikos für Thromboembolien (speziell zur Schlaganfallprophylaxe) weist diverse offene Fragen auf, für deren Beantwortung eine begrenzte evidenzliefernde Datenlage vorliegt.

Publication History

Article published online:
08 June 2023

• Literatur

• 1 De Vriese AS, Caluwé R, Van Der Meersch H. et al Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial. J Am Soc Nephrol 2021; 32: 1474-1483
• 2 Pokorney SD, Chertow GM, Al-Khalidi HR. et al Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial. Circulation 2022; 146: 1735-1745
• 3 Reinecke H, Engelbertz C, Bauersachs R. et al A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study. Circulation 2023; 147: 296-309
• 4 De Vriese AS, Caluwé R, Bailleul E. et al Dose-finding study of rivaroxaban in hemodialysis patients. Am J Kidney Dis 2015; 66: 91-98
• 5 De Vriese AS, Caluwé R, Pyfferoen L. et al Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hemodialysis Patients with Atrial Fibrillation: the Valkyrie Study. J Am Soc Nephrol 2020; 31: 186-196
• 6 Kuno T, Takagi H, Ando T. et al Oral Anticoagulation for Patients With Atrial Fibrillation on Long-Term Hemodialysis. J Am Coll Cardiol 2020; 75: 273-285
• 7 De Vriese AS, Heine G. Anticoagulation management in haemodialysis patients with atrial fibrillation: evidence and opinion. Nephrol Dial Transplant 2022; 37: 2072-2079
• 8 Genovesi S, Porcu L, Slaviero G. et al Outcomes on safety and efficacy of left atrial appendage occlusion in end stage renal disease patients undergoing dialysis. J Nephrol 2021; 34: 63-73